TheraVida is a Chapel Hill, North Carolina based clinical stage specialty pharmaceutical company focused on the development of Anhydrix™ for the treatment of primary focal hyperhidrosis. Anhydrix™’s systemic approach gives it the unique potential to address patients suffering from both primary focal and secondary generalized hyperhidrosis.

We successfully completed a Phase 2 trial of Anhydrix™ and licensed the product to Dermavant Sciences for worldwide development.

Using a unique and patent-protected combination drug technology, we are developing a pharmaceutical product with an improved tolerability profile relative to existing therapies. Our technology has been shown in initial clinical trials to deliver this benefit without sacrificing efficacy.

Our lead combination drug product, Anhydrix™, has successfully completed a phase 2 human study for the treatment of primary focal hyperhidrosis.